- Home
- EQ vs BNGO Comparison
EQ vs BNGO Comparison
Compare EQ & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- BNGO
- Stock Information
- Founded
- EQ 2017
- BNGO 2003
- Country
- EQ United States
- BNGO United States
- Employees
- EQ N/A
- BNGO N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- BNGO Biotechnology: Laboratory Analytical Instruments
- Sector
- EQ Health Care
- BNGO Industrials
- Exchange
- EQ Nasdaq
- BNGO Nasdaq
- Market Cap
- EQ 24.8M
- BNGO 24.3M
- IPO Year
- EQ 2018
- BNGO 2018
- Fundamental
- Price
- EQ $0.63
- BNGO $0.19
- Analyst Decision
- EQ Buy
- BNGO Hold
- Analyst Count
- EQ 2
- BNGO 3
- Target Price
- EQ $5.00
- BNGO $1.00
- AVG Volume (30 Days)
- EQ 130.9K
- BNGO 16.7M
- Earning Date
- EQ 11-13-2024
- BNGO 03-04-2025
- Dividend Yield
- EQ N/A
- BNGO N/A
- EPS Growth
- EQ N/A
- BNGO N/A
- EPS
- EQ N/A
- BNGO N/A
- Revenue
- EQ $45,914,000.00
- BNGO $33,334,000.00
- Revenue This Year
- EQ $4.76
- BNGO N/A
- Revenue Next Year
- EQ N/A
- BNGO $6.18
- P/E Ratio
- EQ N/A
- BNGO N/A
- Revenue Growth
- EQ 7.70
- BNGO N/A
- 52 Week Low
- EQ $0.49
- BNGO $0.17
- 52 Week High
- EQ $3.25
- BNGO $1.36
- Technical
- Relative Strength Index (RSI)
- EQ 37.33
- BNGO 39.40
- Support Level
- EQ $0.49
- BNGO $0.17
- Resistance Level
- EQ $0.73
- BNGO $0.26
- Average True Range (ATR)
- EQ 0.08
- BNGO 0.05
- MACD
- EQ -0.01
- BNGO -0.01
- Stochastic Oscillator
- EQ 38.92
- BNGO 7.38
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.